Opinion: STAT+: Dementia finally has a business model

In the nine years since my last visit to the Docklands’ Excel conference center for the 2017 annual Alzheimer Association International Conference, or AAIC, little of London’s infrastructure has changed. I traveled via the same low-ceilinged, clattering trains with signs advising riders to “mind the gap” and “mind the step.” The center has the same weird jack-o’-lantern-esque façade and forgettable restaurants and hotels. I was even here for the same conference.

Same meeting, in the same place, but what transpired was quite different. In just nine years, how we think about the aging brain has transformed.

One moment captured this. It was a speaker’s remark at a breakfast meeting convened by the Davos Alzheimer’s Collaborative. The 5-year-old organization describes itself as “uniting leading organizations worldwide to build an innovation ecosystem that will accelerate breakthroughs, develop and scale promising solutions and equip every healthcare system to end Alzheimer’s disease everywhere.”

Continue to STAT+ to read the full story…

Solving the Mystery of Why Blocking and Stimulating a Brain Receptor Helps Weight Loss

Researchers headed by a team at the Institute of Metabolic Science, University of Cambridge, have solved the mystery of why both stimulating and blocking a particular receptor, or switch, in the brain can help people lose weight. Their study in mice indicated that the answer lies in where the receptor, called GIPR, is located. The results showed that stimulating this switch in the brainstem suppresses appetite, while the same effect can be achieved by blocking it in the hypothalamus. The researchers say their findings could help in the development of more effectiveness therapeutic strategies.

Jo Lewis, PhD, at the Institute of Metabolic Science at the University of Cambridge, said, “Understanding which brain circuits respond to these medications—and how they do so—could help us design better drugs that produce more weight loss with fewer side effects, and which might work in combination with other obesity medicines to even greater effect.” Lewis is first author of the team’s published paper in Nature Metabolism, titled “Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism.”

More than a billion people worldwide are living with obesity, which increases the risk of diseases such as type 2 diabetes (T2D), cardiovascular disease (CVD) and cancer. Weight loss can help mitigate these complications, but losing weight through diet and exercise alone can prove challenging.

In the past few years, a new generation of weight loss drugs has emerged that target particular receptors in the brain, reducing appetite and leading to weight loss, as well as helping to control blood sugar levels. Several of these drugs, such as Wegovy and Ozempic, work by stimulating the glucagon-like peptide 1 receptor (GLP-1R).

Other weight loss drugs act on both this receptor and on GIPR. “The development of dual agonists for the glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) has been a landmark moment in the treatment of type 2 diabetes and obesity,” the authors wrote.

However, some drugs, such as Mounjaro and Zepbound, stimulate GIPR, while others, such as the Phase III-stage MariTide, block it. Why these opposite actions have the same result has puzzled scientists. “… for reasons that are incompletely understood, in preclinical and clinical studies, adding either a GIPR agonist or GIPR antagonist to GLP-1R agonism causes additional weight loss,” the team continued. “There is emerging evidence that GIPR agonism and antagonism exert their paradoxically similar effects on weight loss via distinct neuronal populations.”

The investigators’ newly reported preclinical research has now shown that the two different types of GIPR drugs act on distinct regions of the brain, but also that they can boost weight loss when combined with certain GLP-1-based weight-loss drugs. For their reported study the team turned to genetically engineered mice and selectively removed GIPR from different parts of the brain to see which regions were responsible for the effects of the obesity drugs.

One group of mice lacked GIPR in the brainstem—the area at the base of the brain, just above the spinal cord, involved in appetite and nausea. A second group lacked GIPR in the hypothalamus, a major center controlling hunger and body weight. A third, control group included normal, unmodified mice. The researchers treated the mice with various combinations of a GIPR agonist (which activates the receptor), a GIPR antagonist (which blocks the receptor) and a GLP-1 drug, and measured food intake, body weight, fat mass, glucose control and brain activity.

“We knock out Gipr in either the area postrema (AP) or hypothalamus of mice (GiprAP-KO  and Giprhypo-KO, respectively) and compare body weight and food intake responses to GIPR agonists and antagonists, alone and in combination with the GLP-1R agonist liraglutide,” they wrote in summary.

By comparing the responses of normal mice with mice lacking GIPR in different brain areas the investigators showed that GIPR agonists act on the brainstem to suppress appetite and reduce weight. They then showed that GIPR antagonists help weight loss by acting on this receptor in the hypothalamus, where they release a “brake” that otherwise limits the brainstem’s ability to respond to signals telling us we are full. Blocking GIPR also appeared to boost the effect of emerging new drugs targeting the amylin receptor—such as cagrilintide (Cagri)—suggesting that GIPR antagonists could potentially be used to strengthen several types of anti-obesity medicines.

“Overall, our results suggest that the AP is responsible for the appetite-suppressing effects of GIPR agonism but that GIP receptors in the hypothalamus underlie the ability of GIPR antagonism to enhance the weight loss effects of GLP-1R and amylin receptor agonists,” they stated. “GIPR antagonism and Giprhypo-KO also sensitize to cagrilintide-induced weight loss.

The findings explain why drugs such as MariTide, which combines GIPR antagonism with GLP-1 receptor agonism, are effective, and suggests how to design even better combination therapies. And as the authors noted, “Future work is still, however, required to identify the neuronal networks underlying GIPR interactions in the AP and hypothalamus and their crosstalk with other appetite-regulating circuitry.”

Lewis said the work strengthens the idea that the brain is central to obesity treatment, commenting, “Obesity drugs are not acting simply on the gut or pancreas. Instead, they have important effects on specific, identifiable brain circuits that regulate appetite and food intake.”

The post Solving the Mystery of Why Blocking and Stimulating a Brain Receptor Helps Weight Loss appeared first on GEN – Genetic Engineering and Biotechnology News.

ALS Could Be Predicted Years Before Symptoms, Proteomics Study Finds

Neurodegenerative diseases are typically defined by the presence of characteristic clinical phenotypes. However, it is increasingly recognized that early intervention could give people the best chance for meaningful positive effects. As a result, early detection and prevention are becoming major priorities.

Months to several years before amyotrophic lateral sclerosis (ALS) symptoms arise, levels of certain blood proteins may dramatically shift. By anticipating the arrival of symptoms, investigators could intervene with preventative therapies before the irreversible motor neuron damage that is characteristic of ALS sets in.

In this study, researchers analyzed data from the long-running, National Institutes of Health (NIH)-funded Pre-symptomatic Familial ALS (Pre-fALS) study, to identify a lineup of key proteins that may predict the emergence of clinically manifest ALS.

This work is published in Nature Medicine in the paper, “Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS.”

“If someone carrying an ALS-associated genetic variant had asked me in the past when they would become symptomatic, I would have struggled to provide a reasonable estimate,” said Michael Benatar, MD, PhD, professor of neurology and public health sciences at the University of Miami. “These biomarkers give us a far better idea of the timing, allowing us to estimate the time to symptom onset with an average error of about 18 months. That’s something we can work with.”

For nearly 20 years, the Pre-fALS study has collected data and biological samples from people who are at significantly elevated genetic risk for ALS but have not yet progressed, or phenoconverted, to the disease. While this cohort is unique, permitting the examination of presymptomatic ALS, recent studies suggest that findings from Pre-fALS are likely relevant to the broader population.

In 2017, an analysis of ten Pre-fALS participants who had developed symptoms showed that neurofilament light chain (NfL), a structural protein in neurons, spiked in their blood in the months preceding ALS phenoconversion. As more study participants have begun showing symptoms or signs of disease, new opportunities to search for other pre-symptomatic ALS biomarkers have emerged.

Now, using Olink Explore, investigators report a high-throughput, proteomic study on 516 serially collected plasma samples from 137 study participants; 33 phenoconverters, 35 patients with ALS, 10 pre-symptomatic pathogenic variant carriers and 59 controls.

The team identified 92 whose levels differed in people before they eventually showed symptoms. Using machine-learning techniques, the authors tested how various combinations of proteins could predict future risk of phenoconversion. Characterizing the longitudinal trajectory of these proteins, they identified a core panel of 19 proteins (including NfL) which, collectively, the authors note, predicted phenoconversion over the 0.5-year to 5-year time horizons and yielded estimates of time to phenoconversion with a mean absolute error of 1.6 years.

They also produced similar results using data from the UK Biobank, which, despite some limitations, is more representative of the general population than the genetically predisposed cohort of Pre-fALS.

“With preventative gene-targeting treatments now becoming available, there is a particularly urgent need for reliable biofluid-based signatures that indicate near-term onset in individuals that carry ALS risk genes,” said Amy Bany Adams, PhD, acting director of NIH’s National Institute of Neurological Disorders and Stroke (NINDS).

Tofersen, a drug approved for symptomatic ALS, is currently being evaluated as a preventative therapeutic in pre-symptomatic ALS through ATLAS, a clinical trial designed by Benatar in partnership with the company Biogen. ATLAS will test whether starting treatment shortly before symptoms appear could avert or delay the onset of ALS.

“This is all possible because of the members of the carrier community who believe in our mission of preventing ALS and have supported and participated in our research. It has been one of my life’s greatest privileges to give something back,” Benatar said.

The post ALS Could Be Predicted Years Before Symptoms, Proteomics Study Finds appeared first on GEN – Genetic Engineering and Biotechnology News.

How lasers could help provide fuel for nuclear reactors

Outside the small town of Paducah, Kentucky, a wealth of uranium is locked away in thousands of storage cylinders filled with waste material from a now-closed nuclear enrichment facility. Lasers could help get it out.

A company called Global Laser Enrichment (GLE) is looking to reprocess this old material with a new technology called laser enrichment. It could be more efficient than conventional enrichment methods, allowing the company to refresh the material and produce feedstock at the same concentration as a natural mined source. And in the future, the company claims, laser enrichment could be used to make material for nuclear fuel, including the kind used in advanced reactors.

Nuclear power provides about 9% of global electricity today, and that fraction could tick up as major world powers like the US and China look to build new reactors, including some based on next-generation technology. New, cheaper methods to obtain fuel could help ensure that those nuclear projects stay on track.

Naturally occurring uranium is largely made up of uranium-238 (over 99%) and uranium-235 (about 0.7%). Uranium-235 is the fissile type, meaning that, when hit with slow low-energy neutrons, it can sustain a chain reaction that generates electricity. So reactors generally use material with a higher concentration of U-235 than what’s pulled from the ground. Today’s conventional reactors usually use low-enriched uranium, typically is about 5% U-235, though some advanced reactor designs will use fuel that’s up to 20% U-235.

Today, centrifuges are the dominant tech used to enrich uranium. The equipment essentially takes uranium-containing material and spins it around incredibly quickly, so the heavier material (which contains U-238) spins out to the edge, while the lighter material (which has U-235) stays closer to the center. (If you’ve ever swung a mustard bottle to get the last of it out, you’ve used the same basic idea behind a centrifuge.) Then the material that has a higher concentration of U-235 can go on to be made into nuclear fuel.

Laser enrichment, on the other hand, takes advantage of the fact that all molecules vibrate and rotate at an atomic scale in ways that depend on their specific material. Even different uranium isotopes have distinct fingerprints.

Lasers are so precise they can target one particular material (like molecules that contain U-235, for example). If you shine a laser at a mixture, you can selectively excite just the material you’re targeting, giving it a bit more energy. This changes the way it behaves, which can make it easier to separate out the material you want using chemical or physical methods.

A wide range of separation approaches have been developed in research and industry. Some aim to electrically charge U-235 atoms, allowing them to be moved with electrostatic or magnetic fields. Others change how the material reacts chemically. 

The details of GLE’s specific technology are classified, and company officials declined to share how the process works. 

There’s been interest in using lasers for uranium enrichment for decades, says Charles Forsberg, a principal research scientist in nuclear science and engineering at MIT. 

However, in their early days lasers tended to be high-maintenance, unstable and difficult to operate. They’ve improved dramatically, making laser enrichment a more attractive prospect than it was during the early research.

Even more than technological improvements, a recent geopolitical shift could boost new enrichment technology. Russia has the largest uranium enrichment ecosystem in the world, and the country has historically dominated the market. “Nobody in the West was going to build a new enrichment plant while the Russians flooded the world with enriched uranium,” says Forsberg. 

Since the start of the Ukraine war, however, countries including the US and UK have taken steps to limit or ban imports of Russian uranium. That’s opened the door for companies to set up new enrichment operations, including some that use new technologies, Forsberg says.

Demand for fuel is increasing as countries look beyond Russia for uranium supply. “The gap is just becoming bigger and bigger, and this technology is right in the middle,” says Christo Liebenberg, president of LIS Technologies, one of the companies aiming to build laser enrichment capacity in the US.

LIS Technologies was founded in 2023, and the company recently purchased a 200-acre site in Oak Ridge, Tennessee. It’s currently in the pre-application process with the US Nuclear Regulatory Commission for its facility. The company plans to take in natural-grade uranium and make a product that’s roughly 5% U-235, though it hopes to eventually make more concentrated material that can be used as fuel for next-generation reactors.

GLE is taking a different approach: Rather than using its technology to enrich freshly mined material to the 5% concentration that can be used in fuels, it’s hoping to start by rehabilitating old waste.

The company has a contract with the US Department of Energy to reprocess waste material at the enrichment site in Paducah. The facility could enrich up to 200,000 metric tons of material that contains small amounts of uranium leftover from an older enrichment process.

GLE is taking the material that’s at least 0.25% U-235 and enriching it to about 0.7%. That material can then be further processed and slotted into the uranium supply chain in place of freshly mined material. “It’s kind of like a large aboveground uranium mine for us,” says Nima Ashkeboussi, vice president of government relations and communications at GLE.

While each one of its units is more complex and expensive than a centrifuge, far fewer are needed to do the same work. A similar centrifugation plant would have many thousands of centrifuges working together, but a full-scale plant using GLE’s laser enrichment process would have fewer than a thousand of its units, says Stephen Long, the company’s CEO. Up-front investment should be smaller, and operating costs are also expected to be lower, partly because the process uses less energy than centrifuges, Long says.

GLE has a testing facility in Wilmington, North Carolina. In fall 2025, the company completed a demonstration pilot, processing several hundred kilograms of uranium. It decommissioned that system and is currently putting together a new demonstration at the North Carolina plant, which would show how the technology works at commercial scale.

The company also applied for a license with the US Nuclear Regulatory Commission for its proposed facility in Paducah. The final safety evaluation should be finished in November, and the final approval should come in 2027, Long says. The plan is to start processing material at the plant by 2030.

In the long run, there’s plenty of uranium on the planet to keep reactors running for decades. But as interest in nuclear power grows and the geopolitics of fuel shift, there could be short-term gaps or price spikes that alternative sources could help smooth out.

Laser enrichment plants could turn out to be cheaper than existing technologies, says Stephen Greene, a senior fellow at the Nuclear Innovation Alliance. But as with most new technologies, “you don’t really know until you try to build one.”

The Download: lasers for nuclear fuel, and organ preservation advances

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.

How lasers could help provide fuel for nuclear reactors 

Nuclear power provides about 9% of global electricity today, and that fraction could tick up as countries look to build new reactors. New, cheaper methods to obtain fuel could help ensure that those nuclear projects stay on track.

One of those methods is called laser enrichment. It allows you to separate out the material you want (in this case, uranium) from others in a mixture of old waste.

A company called Global Laser Enrichment (GLE) is about to start testing whether the technology works at commercial scale. Read our story about their efforts.

—Casey Crownhart

The quest to keep organs alive outside the body

It’s super difficult to freeze organs. Once ice forms in them, they’re done. The ice crystals create all kinds of damage and render the organs unusable. That hasn’t stopped many researchers from trying.

In new research, one team has been able to supercool the kidneys of pigs and preserve them for days. The kidneys survived being stored at −4 °C (25 °F) and eventually reimplanted back into pigs. And that’s just the latest development in a field that is positively buzzing.

Read about why it’s such an exciting time for organ preservation—and what could be coming next. 

—Jessica Hamzelou

This story is from The Checkup, our weekly biotech newsletter. Sign upto receive it in your inbox every Thursday.

The must-reads

I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.

1 Silicon Valley is split over how to respond to Chinese AI
It boils down to whether AI models should be open or closed. (NYT $)
+ Nvidia, Microsoft and Meta warn that restricting open models would backfire. (CNBC)
+ AI companies are spending record sums on lobbying Washington. (FT $)
+ China’s AI models have Trump’s AI world at war with itself. (MIT Technology Review)

2 Trump can’t post his way out of this war 
Iran has revealed hard limits to his ability to bend reality to his will. (Atlantic $)
+ Trump has been forced to abandon further escalation due to dwindling munitions stockpiles. (NYT $)
+ An Iranian strike on CIA facilities has raised questions about Russian involvement. (Reuters $)

3 Wildfires are surging across Europe
Repeated heat waves have turned parts of the continent into a tinder box. (BBC)
+ One of the fires forced NASA to evacuate a tracking station in Spain. (Ars Technica)
+ Americans are increasingly grappling with smoky skies too. (Atlantic $)

4 OpenAI didn’t notice its agent going on a days-long hacking spree
It only cottoned on after the threat was contained and the FBI had been alerted, sources say. (Reuters $)

5 The AI jobs wipeout still hasn’t arrived
In fact, a lot of companies are now embarking on hiring sprees. (WSJ $)
+ AI’s impact is increasingly falling short of expectations. (The Guardian) 
+ Here’s a much-needed reality check on the AI jobs hysteria. (MIT Technology Review)

6 A six-year-old girl died in a Chinese gene-editing trial
Experts say it should have never been allowed to go ahead. (Science)
+ This baby boy was treated with the first personalized gene-editing drug. (MIT Technology Review)

7 What it’s like to use a North Korean smartphone
They’re growing in popularity—but represent another avenue for government control. (WP $)

8 The FCC’s ban on foreign-made drones is not working
You can’t change global supply chains at the stroke of a pen. (The Verge $)

9 The “summer of Ludd” shows it’s fun to be a Luddite 
A growing anti-tech movement is all about raw, anarchic joy. (404 Media)
+ We’re in the era of AI malaise. (MIT Technology Review)

10 Why Jimothy the racoon is the internet’s latest obsession ?
It’s his irresistible combination of chaos and cuteness. (BBC)

Quote of the day

“I think that [AI] should stand for artificial idiot.”

—Marian Agnew, a nine-year-old, from Norman, Oklahoma, tells Wired she’s not impressed by AI models’ tendency to make up facts.  

One More Thing

three silhouetted people in a boat crossing the water in the dark toward a beam of light

KATHERINE LAM

Inside a romance scam compound—and how people get tricked into being there  

Gavesh’s journey started, seemingly innocently, with a job ad on Facebook promising work he desperately needed. 

Instead, he found himself trafficked into a business commonly known as “pig butchering”—a form of fraud in which scammers form close relationships with targets online and extract money from them. 

The Chinese crime syndicates behind the scams have netted billions of dollars, and they have used violence and coercion to force their workers to carry out the frauds from large compounds, several of which operate openly in the quasi-lawless borderlands of Myanmar. 

Read our story about these scam syndicates and how they could be broken up. 

— Peter Guest and Emily Fishbein

We can still have nice things

A place for comfort, fun, and distraction to brighten up your day. (Got any ideas? Drop me a line.)

+ I want to make every single one of these delicious-looking Korean dishes. 
+ If you like origami, you’ll love this guy’s tutorials.
+ How to deal with those old gadgets that are collecting dust in your drawer.
+ Enjoy these old art deco public transport posters from London.

Molecular Atlas of Severe Preeclampsia Reveals New Therapeutic Targets

Researchers from University College London in England have created the most comprehensive molecular map to date of severe preeclampsia, uncovering distinct fetal and maternal drivers of the disease that could lead to more targeted therapies and earlier intervention.

The study, published in Science Advances, combined single-cell RNA sequencing with spatial transcriptomics across the entire fetal-maternal interface and found that severe preeclampsia is not solely a placental disorder. Instead, the disease involves coordinated dysfunction across multiple maternal and fetal tissues, with different molecular programs emerging in early- versus late-onset disease.

Preeclampsia affects 2% to 4% of pregnancies worldwide and remains a leading cause of maternal and fetal illness and death. Although it is traditionally viewed as a placental disease, the mechanisms responsible for widespread maternal inflammation and endothelial dysfunction have remained unclear.

To better define those mechanisms, investigators analyzed tissues from 20 pregnancies, including 10 women with severe preeclampsia and 10 gestational age-matched controls between 25 and 37 weeks of gestation. By matching pregnancies by gestational age rather than comparing preterm cases with healthy term pregnancies, the researchers were able to distinguish disease-related molecular changes from normal developmental differences.

The analysis revealed extensive placental abnormalities, including molecular signatures of hypoxia, angiogenic imbalance, fibrosis, and altered metabolism. The team also confirmed impaired invasion of fetal extravillous trophoblasts into the maternal uterus, a hallmark of preeclampsia that contributes to defective remodeling of maternal blood vessels.

Beyond the placenta, however, the study identified previously unrecognized maternal immune abnormalities extending into the myometrium and chorioamniotic membranes. These included widespread mitochondrial dysfunction, activation of type I interferon signaling, and altered macrophage responses, providing a potential explanation for the systemic inflammation and endothelial injury that characterize severe disease.

The findings point to several potential therapeutic targets. Leptin (LEP), which was strongly upregulated in placental cells throughout both early and late disease, may contribute to oxidative stress and vascular dysfunction. The researchers suggest that leptin antagonists, already under investigation for autoimmune diseases, warrant exploration as placental-targeted therapies.

The study also highlights type I interferon signaling as a promising target. Elevated interferon activity, detected in maternal immune cells and peripheral blood, could potentially serve as both a biomarker and a therapeutic target for anti-interferon or antioxidant treatments.

“IFN-I in peripheral blood promises better screening of patients that might benefit from anti-IFN or antioxidant therapeutics,” the authors concluded.

Perhaps most importantly, the molecular abnormalities were substantially more pronounced in early-onset disease, suggesting that intervention before clinical deterioration may offer the greatest benefit.

“Given the severity of molecular dysfunctions in early disease, compared to its late presentation, timely intervention during gestation is likely beneficial and could change the extremely poor prognosis of severe PE,” the authors wrote.

The post Molecular Atlas of Severe Preeclampsia Reveals New Therapeutic Targets appeared first on Inside Precision Medicine.

Effects of music interventions on disorders of consciousness: a systematic review and meta-analysis

ObjectiveThe study aimed to systematically evaluate the effects of music intervention on outcomes related to the recovery of consciousness in patients with disorders of consciousness (DOC).MethodsDatabases including PubMed, Web of Science, Embase, the Cochrane Library, China National Knowledge Infrastructure (CNKI), and ProQuest were systematically searched from January 1970 to December 2025 to identify relevant randomized controlled trials (RCTs). The literature was screened based on pre-established inclusion and exclusion criteria, and the review was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The methodological quality of the included studies was assessed using the Cochrane Risk of Bias tool (RoB 1).ResultsA total of 12 randomized controlled trials (RCTs) involving 926 patients with disorders of consciousness (DOC) were included. As the types of outcome indicators reported in the included studies varied, the number of studies included for each outcome also differed. Specifically, five studies were included in the analyses of Glasgow Coma Scale (GCS) scores and the GCS-based awakening rate, whereas two studies were included in the analyses of GCS scores of > 8, the Coma Recovery Scale-Revised (CRS-R), and the National Institutes of Health Stroke Scale (NIHSS). A meta-analysis showed that GCS scores were significantly higher in the music intervention group than in the control group (mean difference (MD) = 2.32). The analyses of GCS scores of > 8 showed that a higher proportion of patients in the music intervention group achieved a GCS score of > 8 (odds ratio (OR) = 5.98). The awakening rate also indicated that the music intervention group was significantly superior to the control group (OR = 3.76). For secondary outcomes, the music intervention group showed higher CRS-R scores (MD = 2.86) and lower NIHSS scores (MD = −1.24).ConclusionMusic intervention may help improve consciousness levels and awakening-related outcomes in patients with disorders of consciousness and may serve as a safe and non-invasive adjunctive measure in rehabilitation nursing care. However, more high-quality randomized controlled trials are needed to further verify its effects and mechanisms.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420261354569, Identifier: CRD420261354569.

INTEGRATING EXPOSURE AND RESPONSE PREVENTION AND HABIT REVERSAL TECHNIQUES TO TREAT A TOURETTIC SUBTYPE OF OBSESSIVE-COMPULSIVE DISORDER (TOURETTIC OCD).

Conditions: Obsessive – Compulsive Disorder; Tic Disorder, Chronic Motor or Vocal; Tic Disorders; Tic Disorder, Combined Vocal and Multiple Motor; Tourette Disease; Tourette Disorder; Tourettes Syndrome; Gilles de la Tourette Syndrome

Interventions: Behavioral: Exposure and Response Prevention (ERP); Behavioral: Habit Reversal Training (HbRT; Behavioral: Psychoeducation and Supportive Intervention

Sponsors: University College London Hospitals

Recruiting